glp 1 and chronic kidney disease Frontiers Glucagon-like Peptide-1 Receptor Agonists and
Description
It mimics the natural effects of GLP-1 to reduce appetite, slow digestion, and increase satiety, making it easier to eat less and lose weight
Studies report that between 31% and 38% of candidates have pre-existing diabetes, while an additional 13% to 28% develop new post-transplant diabetes mellitus (PTDM) within the first three years post-transplant
Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing
2015;15:e4
While some providers may see microdosing as a way to ease patients into treatment or reduce side effects, others worry about its risks
